Chan Henry Lee sold $580k of ONC
SVP, General Counsel at BeOne Medicines Ltd.. 1,660 shares at an average of $349.52, traded Feb 4, 2026, filed Feb 6, 2026.
Score components
- +15RoleOfficer
- +19Trade size$580k at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -14.9%, 3m -11.8%, 6m -1.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001980648-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 4, 2026 | MOption exercise American Depositary Shares10b5-1 | +502 | $194.47 | $98k | 502 | Feb 6, 2026 |
| Feb 4, 2026 | MOption exercise American Depositary Shares10b5-1 | +662 | $213.32 | $141k | 1,164 | Feb 6, 2026 |
| Feb 4, 2026 | MOption exercise American Depositary Shares10b5-1 | +496 | $159.03 | $79k | 1,660 | Feb 6, 2026 |
| Feb 4, 2026 | SOpen-market sale American Depositary Shares10b5-1 | -664 | $348.79 | $232k | 996 | Feb 6, 2026 |
| Feb 4, 2026 | SOpen-market sale American Depositary Shares10b5-1 | -996 | $350.00 | $349k | 0 | Feb 6, 2026 |
| Feb 4, 2026 | MOption exercise Share Option (Right to Buy)derivative10b5-1 | -6,526 | $0.00 | $0 | 23,920 | Feb 6, 2026 |
| Feb 4, 2026 | MOption exercise Share Option (Right to Buy)derivative10b5-1 | -8,606 | $0.00 | $0 | 88,413 | Feb 6, 2026 |
| Feb 4, 2026 | MOption exercise Share Option (Right to Buy)derivative10b5-1 | -6,448 | $0.00 | $0 | 111,670 | Feb 6, 2026 |
Related signals
Other insiders at BeOne Medicines Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 39Weak | BeOne Medicines Ltd. | Chan Henry Lee SVP, General Counsel | $418k 1,115 shares | -100% | |
| 33Weak | BeOne Medicines Ltd. | Xiaodong Wang director, other | $11M 31,028 shares | -100% | |
| 33Weak | BeOne Medicines Ltd. | Xiaodong Wang director, other | $13M 38,287 shares | -527% | |
| 49Moderate | BeOne Medicines Ltd. | Titus B. Ball Principal Accounting Officer | $47k 132 shares | -100% | |
| 84Strong | BeOne Medicines Ltd. | John Oyler Chief Executive Officer | $934k 3,410 shares | -100% | |
| 70Notable | BeOne Medicines Ltd. | Xiaobin Wu President and COO | $357k 1,292 shares | -100% | |
| 69Notable | BeOne Medicines Ltd. | Lai Wang President, Global Head of R&D | $296k 1,068 shares | -100% | |
| 85Strong | BeOne Medicines Ltd. | John Oyler Chief Executive Officer | $981k 3,693 shares | -100% | |
| 70Notable | BeOne Medicines Ltd. | Xiaobin Wu President and COO | $362k 1,357 shares | -100% | |
| 69Notable | BeOne Medicines Ltd. | Lai Wang President, Global Head of R&D | $310k 1,169 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.